Chronic Pruritus | VPD-737 for Treatment of Chronic Pruritus

Chronic Pruritus research study

What is the primary objective of this study?

A study of a several doses of a novel treatment for chronic itch compared to placebo for patients whose condition has not responded to other treatments

Who is eligible to participate?

Inclusion Criteria: - Clinical diagnosis of chronic pruritus and unresponsive to current therapies Exclusion Criteria: - Have chronic liver or renal disease

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Chronic Pruritus

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:VPD-737NK1 Receptor Antagonist


Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

0.25 mg VPD-7370.25 mg of VPD-737 daily by mouth for 42 days

1 mg VPD-7371 mg VPD-737 taken daily by mouth for 42 days

5 mg VPD-7375 mg tablets of VPD-737 to be taken daily by mouth for 42 days

Placeboplacebo tablets to be taken daily by mouth for 42 days

Study Status


Start Date: October 2013

Completed Date: April 2015

Phase: Phase 2

Type: Interventional


Primary Outcome: Visual Analog Scale

Secondary Outcome: Verbal Response Scale

Study sponsors, principal investigator, and references

Principal Investigator: Edward F Schnipper, MD

Lead Sponsor: Menlo Therapeutics Inc.


More information:

Discuss Pruritus